ABSTRACT We present a case series of four patients who had scabies diagnosed while on Dupilumab treatment for atopic dermatitis. The Type 2 immune response is the primary immune response for both ordinary and crusted scabies, and Dupilumab inhibits this response. This inhibition could be the reason behind treatment resistance and crusted presentations in this case series. Clinicians should be aware of the possible development of scabies in patients on Dupilumab and the potential of scabies masquerading as atopic dermatitis at the time of instituting this medication.